Rational design of potent antagonists to the human growth hormone receptor.

A hybrid receptor was constructed that contained the extracellular binding domain of the human growth hormone (hGH) receptor linked to the transmembrane and intracellular domains of the murine granulocyte colony-stimulating factor receptor. Addition of hGH to a myeloid leukemia cell line (FDC-P1) that expressed the hybrid receptor caused proliferation of these cells. The mechanism for signal transduction of the hybrid receptor required dimerization because monoclonal antibodies to the hGH receptor were agonists whereas their monovalent fragments were not. Receptor dimerization occurs sequentially--a receptor binds to site 1 on hGH, and then a second receptor molecule binds to site 2 on hGH. On the basis of this sequential mechanism, which may occur in many other cytokine receptors, inactive hGH analogs were designed that were potent antagonists to hGH-induced cell proliferation. Such antagonists could be useful for treating clinical conditions of hGH excess, such as acromegaly.

[1]  S. Nagata,et al.  Expression cloning of a receptor for murine granulocyte colony-stimulating factor , 1990, Cell.

[2]  C. March,et al.  A new cytokine receptor superfamily. , 1990, Trends in biochemical sciences.

[3]  L. Patthy.  Homology of a domain of the growth hormone/prolactin receptor family with type III modules of fibronectin , 1990, Cell.

[4]  S. Nagata,et al.  Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. , 1990, The Journal of biological chemistry.

[5]  T. Wagner,et al.  Glycine 119 of bovine growth hormone is critical for growth-promoting activity. , 1991, Molecular endocrinology.

[6]  William I. Wood,et al.  Growth hormone receptor and serum binding protein: purification, cloning and expression , 1987, Nature.

[7]  M. Waters,et al.  Evidence from the use of monoclonal antibody probes for structural heterogeneity of the growth hormone receptor. , 1985, The Biochemical journal.

[8]  S. Bass,et al.  The human growth hormone receptor. Secretion from Escherichia coli and disulfide bonding pattern of the extracellular binding domain. , 1990, The Journal of biological chemistry.

[9]  L. Frohman.  Clinical review 22: Therapeutic options in acromegaly. , 1991, The Journal of clinical endocrinology and metabolism.

[10]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Clauser,et al.  Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. , 1991, Science.

[12]  J. Wells,et al.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.

[13]  M. Ultsch,et al.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. , 1992, Science.

[14]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Kunkel.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Cunningham,et al.  Rational design of receptor-specific variants of human growth hormone. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Henner,et al.  Engineering human prolactin to bind to the human growth hormone receptor. , 1990, Science.

[18]  S. Nagata,et al.  Functional domains of the granulocyte colony‐stimulating factor receptor. , 1991, The EMBO journal.

[19]  J. Wells,et al.  A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.